Rhythm Pharmaceuticals Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
RYTM Nasdaq 8731 http://www.rhythmtx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc. (RYTM): Short Seller Sentiment is Bearish - Sep 21st, 2024 6:23 am
Strength Seen in Rhythm Pharmaceuticals (RYTM): Can Its 7.4% Jump Turn into More Strength? - Sep 18th, 2024 2:46 pm
Rhythm Pharmaceuticals Announces New Employment Inducement Grants - Sep 16th, 2024 8:01 pm
Biotech Stock Near Buy Point Amid Impressive Sales Track Record - Sep 10th, 2024 5:55 pm
Four Biotech Stocks Rally Toward Buy Points As Funds Load Up - Sep 6th, 2024 5:31 pm
Biotech Stock Roundup: REGN's Drug Approval, LXRX, RYTM Stocks Gain on Update & More - Aug 28th, 2024 2:11 pm
High Growth Tech Stocks To Watch In August 2024 - Aug 27th, 2024 2:04 pm
Rhythm Pharmaceuticals Announces FDA Acceptance for Priority Review of Supplemental New Drug Application for IMCIVREE® (setmelanotide) in Patients as Young as 2 years old - Aug 26th, 2024 12:02 pm
Rhythm Pharmaceuticals to Present at Wells Fargo Healthcare Conference in September - Aug 26th, 2024 12:00 pm
Analysts Are Updating Their Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Estimates After Its Second-Quarter Results - Aug 9th, 2024 10:35 am
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates - Aug 6th, 2024 12:15 pm
Rhythm Pharmaceuticals Reports Second Quarter 2024 Financial Results and Business Update - Aug 6th, 2024 11:00 am
Rhythm Pharmaceuticals Announces European Commission Expands ▼IMCIVREE® (setmelanotide) Marketing Authorization to include Children as Young as 2 Years Old - Jul 31st, 2024 1:10 pm
Rhythm Pharmaceuticals Announces First Patients Dosed in Phase 2 Trial Evaluating Oral MC4R Agonist LB54640 in Hypothalamic Obesity - Jul 23rd, 2024 12:00 pm
Rhythm Pharmaceuticals to Report Second Quarter 2024 Financial Results on Tuesday, August 6, 2024 - Jul 23rd, 2024 11:30 am
Rhythm Pharmaceuticals Announces Appointment of Alastair Garfield, Ph.D., as Chief Scientific Officer - Jul 8th, 2024 12:00 pm
Rhythm Pharmaceuticals Receives Positive CHMP Opinion for ▼IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients between 2 and 6 years old with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency - Jun 28th, 2024 12:00 pm
Rhythm Pharmaceuticals Presents Patient-reported Experiences with Hyperphagia in Hypothalamic Obesity at ENDO 2024 - Jun 3rd, 2024 8:02 pm
Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conference - Jun 3rd, 2024 12:02 pm
While Rhythm Pharmaceuticals (NASDAQ:RYTM) shareholders have made 125% in 1 year, increasing losses might now be front of mind as stock sheds 3.2% this week - May 25th, 2024 12:17 pm